Olpasiran cut Lp(a) levels by more than 95% in patients with atherosclerotic CVD - Healio

Retrieved on: 2022-11-07 19:40:35

Tags for this article:

Branches of biology

Drugs

Low-density lipoprotein

Magnesium in biology

Amgen

Medroxyprogesterone acetate

Dipti Itchhaporia

Click the tags to see associated articles and topics

Olpasiran cut Lp(a) levels by more than 95% in patients with atherosclerotic CVD - Healio. View article details on HISWAI: https://www.healio.com/news/cardiology/20221107/olpasiran-cut-lpa-levels-by-more-than-95-in-patients-with-atherosclerotic-cvd

Excerpt

O'Donoghue reports receiving honoraria from Amgen, AstraZeneca, Janssen and Novartis and research grants from Amgen, AstraZeneca, ...

Article found on: www.healio.com

View Original Article